Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly announces TB partnership investment

Eli Lilly announces TB partnership investment

22nd March 2007

Eli Lilly has announced the granting of additional funds to a joint association fighting against multi-drug resistant tuberculosis (MDR-TB). The company has pledged an additional $50 million (25.41 million pounds) investment to the Lilly MDR-TB Partnership.

Bringing the company’s total investment in the collaboration to $120 million, this money will assist it continue its multi-faceted strategy to tackle TB.

The Lilly MDR-TB Partnership aims to increase the availability and supply of effective medication, train healthcare workers and focus worldwide efforts on prevention, diagnosis and treatment of the disease.

Consisting of 14 private and public organisations, the group’s members include businesses, academic institutions, humanitarian groups and professional health care associations.

A key aim of the Lilly MDR-TB Partnership is to influence global policy regarding MDR-TB, such as the introduction of new treatment protocols, while advising that the importance of treating the condition is equitable to that of treating primary TB.

Sidney Taurel, chairman and chief executive officer of Lilly, reported that the firm understood its responsibility to those affected by TB and appreciated its role in the international fight against the disease.

“These additional funds will extend our commitment to transferring the technologies and improving the support systems needed to stop the spread of MDR-TB,” he said.

As a part of its role in the fight against MDR-TB, the company has made available to pharmaceutical firms in China, India, Russia and South Africa the manufacturing technology for caperomycin and cycloserine, two drugs for the treatment of MDR-TB.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.